Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Income from Continuing Operations: 2009-2024

Historic Income from Continuing Operations for Gyre Therapeutics (GYRE) over the last 16 years, with Dec 2024 value amounting to $16.9 million.

  • Gyre Therapeutics' Income from Continuing Operations rose 107.84% to $5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.8 million, marking a year-over-year increase of 112.80%. This contributed to the annual value of $16.9 million for FY2024, which is 119.58% up from last year.
  • Per Gyre Therapeutics' latest filing, its Income from Continuing Operations stood at $16.9 million for FY2024, which was up 119.58% from -$86.3 million recorded in FY2023.
  • Gyre Therapeutics' 5-year Income from Continuing Operations high stood at $16.9 million for FY2024, and its period low was -$87.9 million during FY2021.
  • Over the past 3 years, Gyre Therapeutics' median Income from Continuing Operations value was $3.4 million (recorded in 2022), while the average stood at -$22.0 million.
  • In the last 5 years, Gyre Therapeutics' Income from Continuing Operations tumbled by 2,620.85% in 2023 and then soared by 119.58% in 2024.
  • Gyre Therapeutics' Income from Continuing Operations (Yearly) stood at -$56.3 million in 2020, then plummeted by 56.10% to -$87.9 million in 2021, then soared by 103.89% to $3.4 million in 2022, then slumped by 2,620.85% to -$86.3 million in 2023, then soared by 119.58% to $16.9 million in 2024.